U.S. FDA Approves KEYTRUDA in Combination with WELIREG for Adjuvant Treatment of Renal Cell Carcinoma
The U.S. FDA has approved KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab with berahyaluro...
South Korea's Rznomics Announces Interim Clinical Data for RZ-001 in Treating rGBM
Rznomics' RNA editing-based anticancer gene therapy, RZ-001 (Taspitimagene advec), has demonstrated ...
Ascendis Reports 182-Week Data for YORVIPATH in Hypoparathyroidism
Danish biopharmaceutical company Ascendis Pharma A/S (Nasdaq: ASND) announced 182-week data from the...
University College Dublin Discovers Cinquefoil Extract Can Inhibit Superbugs
A research team at University College Dublin has found that cinquefoil extract can effectively inhib...
Netherlands completes world's first in vivo CRISPR Phase III trial, reducing attacks by 87%
The research team has successfully completed the world's first Phase III trial of an in vivo CRISPR ...
U.S. Celldex Announces Positive Phase 1 Results for CDX-622
U.S. biopharmaceutical company Celldex (NASDAQ: CLDX) presented positive results from a Phase 1 stud...
US-based Parabilis Medicines Sets Drug Developer Fundraising Record with $770 Million IPO
Parabilis Medicines (Nasdaq: PBLS) became the largest IPO in drug developer history last week throug...
Legend Biotech's LB2501 Achieves 100% ORR in High-Dose Cohort in Phase 1 Trial
Legend Biotech Corporation presented Phase 1 clinical proof-of-concept data (Abstract #LB5006) for i...
China's Ascentage Pharma Announces 17 Clinical Updates at EHA2026
Ascentage Pharma Group (NASDAQ: AAPG; HKEX: 6855) announced 17 clinical updates on its core assets, ...
Lilly's First Type II JAK2 Inhibitor Phase 1 Study Shows 70% of Patients Achieve Spleen Reduction
Eli Lilly and Company (Lilly) has announced the first clinical data for its investigational drug AJ1...
Johnson & Johnson's TALVEY Combination Therapy Reduces Risk of Myeloma Progression or Death by 72%
Data from the MonumenTAL-3 clinical trial show that Tal-DP and Tal-D regimens significantly prolonge...
ENDO 2026: Menopausal Hormone Therapy Reduces Risk of Low Bone Density by 69%
A study presented at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Illinois, USA, fo...
China's Akeso's Gumokimab Approved by NMPA for Moderate-to-Severe Plaque Psoriasis
Akeso (9926.HK) announced that the China National Medical Products Administration (NMPA) has approve...
China and Platinum Appoints Patel as Scientific Advisor
Harbour BioMed (HKEx: 02142) announced the appointment of Dr. Dhavalkumar Patel as a scientific advi...
China Unicom Launches Billion-Yuan Support Plan for High-Quality Datasets
At a recent milestone achievement conference held in Beijing, the National Artificial Intelligence A...
Chinese Scientists Propose "Pulsatile Activation" Concept and Develop New Drug for Chronic Liver Disease
The team led by Xu Huaqiang and Li Jia from the Shanghai Institute of Materia Medica, Chinese Academ...
SK Bioscience of South Korea Licenses Rotavirus Vaccine Technology from US CDC
SK bioscience has initiated process development for an injectable rotavirus vaccine candidate. The c...
Switzerland's VERAXA Biotech to List on Nasdaq
VERAXA Biotech AG announced the completion of its business combination with Voyager Acquisition Corp...
Chinese Team's RNA Editing Therapy Shows Efficacy in Treating Rare Disease
A team led by Wei Wensheng, a leading scientist at Changping Laboratory and a professor at Peking Un...
U.S. Incyte to Spend Up to $2 Billion to Expand Hematology Pipeline
On June 8, U.S. biopharmaceutical company Incyte announced it has reached a definitive agreement to ...
Chime Biologics Launches GMP-2 Facility in Wuhan, Plans AI-Driven Super Factory
Chime Biologics announced the official launch of its GMP-2 production facility in Wuhan, China. The ...
U.S. FDA Grants Regenerative Medicine Advanced Therapy Designation to lasme-cel
Cellectis announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medici...
US FDA Approves Eli Lilly's EBGLYSS Every-8-Week Maintenance Dosing Regimen
Eli Lilly and Company announced that the U.S. Food and Drug Administration has approved a maintenanc...
Mayo Clinic Maps Over 500,000 Cells in Meningioma Atlas
Mayo Clinic, in collaboration with the Princess Margaret Cancer Centre in Toronto, published a study...
Brazil's Biomm expects ~3000% Ebitda growth by 2026
Brazilian pharmaceutical company Biomm (the only domestic producer of insulin glargine) has released...
Antengene's ATG-201 Receives IND Approval in China for the Treatment of Autoimmune Diseases
Antengene Corporation announced that the China National Medical Products Administration (NMPA) has a...
German Evotec Appoints Rui Wang as Global Head of Computational Science and Artificial Intelligence
Evotec SE announced the appointment of Rui Wang as Global Head of Computational Science and Artifici...
Brazil's Ávita Care seeks approval for semaglutide weight-loss pen within June
Ávita Care is accelerating the submission of final supplementary materials to Brazil's National Heal...
Zealand's Phase 2 Trial Shows 10.7% Weight Reduction
Zealand Pharma A/S (Zealand Pharma) announced new data from the Phase 2 ZUPREME-1 trial of its amyli...
EU: Hansa Idefirix Achieves 90% One-Year Graft Survival in Kidney Transplantation
Hansa Biopharma has announced positive top-line results from a post-approval efficacy study of Idefi...